Sarepta Therapeutics (SRPT) Asset Writedowns and Impairment (2010 - 2022)

Sarepta Therapeutics' Asset Writedowns and Impairment history runs 6 years deep, the most recent figure standing at $2.6 million for Q4 2022.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $2.6 million in Q4 2022; TTM through Dec 2022 was $7.1 million, a 64.79% increase from a year earlier, with the FY2025 full-year figure at $165.3 million, changed N/A from the prior year.
• Asset Writedowns and Impairment retreated to $2.6 million in Q4 2022 per SRPT's latest filing, from $4.5 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $4.5 million in Q3 2021 and bottomed at -$202000.0 in Q4 2019.
• The 4-year median for Asset Writedowns and Impairment is $2.6 million (2022), against an average of $2.2 million.
• Biggest YoY gain for Asset Writedowns and Impairment was 105.25% in 2019; the steepest drop was 105.25% in 2019.
• Year by year, Asset Writedowns and Impairment stood at $3.8 million in 2018, then tumbled by 105.25% to -$202000.0 in 2019, then jumped by 2321.78% to $4.5 million in 2021, then tumbled by 42.62% to $2.6 million in 2022.
• Per Business Quant, the three latest SRPT Asset Writedowns and Impairment figures stand at $2.6 million (Q4 2022), $4.5 million (Q3 2021), and -$202000.0 (Q4 2019).